4-(5-Hydroxypyridin-2-yl)piperazine-1-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-(5-Hydroxypyridin-2-yl)piperazine-1-carboxylic acid
• 英文别名: 4-(5-hydroxypyridin-2-yl)piperazine-1-carboxylic acid
• 化学式: C₁₀H₁₃N₃O₃
• 分子量: 223.23
• InChiKey: KDTXJRXBFQMMJJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  76.9
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• FURIN INHIBITORS
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：EP3790871A1

  公开（公告）日：2021-03-17
• [EN] FURIN INHIBITORS<br/>[FR] INHIBITEURS DE FURINE
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2019215341A1

  公开（公告）日：2019-11-14

  This invention relates to novel compounds according to Formula (I) which are inhibitors of furin, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of fibrotic diseases, including pulmonary fibrosis, renal fibrosis, liver fibrosis, skin fibrosis, ocular fibrosis, cardiac fibrosis, and other miscellaneous fibrotic conditions. The disclosed compounds may also be useful for treating other furin-mediated conditions, including but not limited to, hypertension, cancer, infectious diseases, and genetic disorders (e.g., cystic fibrosis (CF)), and neurodegenerative disorders.